Evaxion's AI Platform Shows 86% Precision in Phase 2 Cancer Vaccine Trial
Summary
Evaxion announced strong Phase 2 data for its personalized cancer vaccine EVX-01, demonstrating 86% vaccine target precision and durable immune responses, validating its AI-Immunology™ platform.
Key Events
-
Strong Phase 2 Data
The EVX-01 personalized cancer vaccine demonstrated 86% vaccine target precision in advanced melanoma patients, a rate described as 'record-high' compared to other methods.
-
AI Platform Validation
The high success rate validates the predictive power of Evaxion's proprietary AI-Immunology™ platform in identifying therapeutically relevant vaccine targets.
-
Durable Immune Response
Two-year analysis showed durable vaccine-specific immune responses and high de novo T-cell responses following EVX-01 administration.
-
AACR Presentation
The new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 22, 2026.
Analysis
This filing reports highly positive Phase 2 clinical data for Evaxion's lead personalized cancer vaccine, EVX-01, in advanced melanoma patients. The reported 86% vaccine target precision is described as "record-high" and significantly better than other methods, providing strong validation for the company's proprietary AI-Immunology™ platform. The durable immune responses and correlation between AI-prediction scores and response magnitude further reinforce the platform's effectiveness. For a clinical-stage TechBio company with a relatively small market capitalization, such robust data for a lead asset is a critical de-risking event and could significantly enhance investor confidence in its technology and pipeline. The upcoming presentation at AACR will provide further visibility.
At the time of this filing, EVAX was trading at $4.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.5M. The 52-week trading range was $1.25 to $12.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.